Thymoma is a rare cancer that grows from the outer lining cells of the thymus, a small organ sitting just above the heart behind the breastbone. The thymus plays a key role in training immune cells during childhood, and while it gradually shrinks with age, its tissue can still give rise to tumors in adults. About 30% of people with a thymoma have no symptoms at all, and the tumor is discovered incidentally on a chest scan done for another reason.
Where Thymoma Starts and What Makes It Unusual
Thymomas originate from the epithelial cells of the thymus, which sits in a region called the anterior mediastinum, the front-center compartment of the chest. Unlike most cancers, thymomas tend to grow slowly and often stay contained within a capsule for years. They rarely spread to distant organs the way lung or breast cancer does. When thymomas do spread, they typically seed the lining of the chest cavity or the sac around the heart rather than traveling through the bloodstream to the liver or bones.
Thymic carcinoma, a related but distinct diagnosis, also starts in the same thymus lining cells. The critical difference is behavior: thymic carcinomas are more aggressive, grow faster, and are more likely to metastasize. When doctors talk about “thymoma,” they generally mean the slower-growing form. The two are classified together as thymic epithelial tumors but are treated and staged with their differences in mind.
Types of Thymoma
Thymomas are classified by the World Health Organization into subtypes labeled A, AB, B1, B2, and B3. These labels describe how the tumor cells look under a microscope and, more importantly, hint at how the tumor is likely to behave.
- Type A: Made up of bland, spindle-shaped cells with very few immature immune cells mixed in. This is the most indolent type and carries the best prognosis.
- Type AB: Similar spindle-shaped cells, but with pockets of immature immune cells scattered throughout. Still generally slow-growing.
- Type B1: Closely resembles normal thymus tissue, with abundant immature immune cells and small clusters of epithelial cells. It behaves relatively well but is a step up in aggressiveness from types A and AB.
- Type B2: Has larger, more prominent clusters of epithelial cells intermingled with immature immune cells. More likely to invade surrounding tissue.
- Type B3: Composed of sheets of mildly abnormal epithelial cells with very few immune cells. This subtype sits closest to thymic carcinoma on the aggressiveness spectrum.
In practice, knowing the subtype helps your medical team predict how the tumor will act after surgery and whether additional treatment is warranted.
Symptoms and How Thymoma Is Found
The most common symptoms are nonspecific: chest discomfort or pain, a persistent cough, and shortness of breath. These occur when the tumor presses on nearby structures in the chest. If the tumor grows aggressively, it can compress the large vein that returns blood from the upper body to the heart, causing swelling of the face, neck, and arms (a condition called superior vena cava syndrome). Pressure on the nerve that controls the diaphragm can cause difficulty breathing on one side. Stridor, a high-pitched breathing sound, and trouble swallowing are late signs caused by compression of the windpipe or esophagus.
Many thymomas, however, produce no local symptoms at all. They show up as an unexpected shadow on a chest X-ray or CT scan ordered for something else entirely.
The Link to Myasthenia Gravis
Thymoma has an unusually strong connection to autoimmune diseases, and the most well-known is myasthenia gravis, a condition where the immune system attacks the connections between nerves and muscles. This causes muscle weakness that worsens with activity, often starting in the eyelids and face before affecting the limbs and breathing muscles.
Roughly 10 to 30% of people diagnosed with myasthenia gravis turn out to have a thymoma. A large pooled analysis estimated the figure at about 21%. The relationship works in both directions: a significant portion of thymoma patients are first identified because they develop myasthenia gravis symptoms that prompt imaging of the chest. Other autoimmune conditions linked to thymoma include pure red cell aplasia (where the bone marrow stops making red blood cells) and hypogammaglobulinemia (low levels of infection-fighting antibodies), though these are less common.
How Thymoma Is Staged
Staging describes how far the tumor has spread, and it drives the treatment plan. The system most widely used in practice is the Masaoka-Koga classification, which has four main stages.
- Stage I: The tumor is completely surrounded by its capsule, with no invasion visible even under a microscope. This is the most favorable stage.
- Stage II: The tumor has broken through or grown into its capsule. In Stage IIA, the breach is only visible under a microscope. In Stage IIB, the tumor visibly invades surrounding fat tissue or is adherent to the chest lining or the sac around the heart.
- Stage III: The tumor has grown directly into a neighboring organ, such as the pericardium, a major blood vessel, or the lung.
- Stage IV: In Stage IVA, the tumor has seeded the chest lining or heart sac with separate nodules. In Stage IVB, there is spread through lymph nodes or the bloodstream to distant sites.
A newer TNM staging system also exists and is increasingly used alongside Masaoka-Koga. It uses the same general logic (tumor size, node involvement, metastasis) but defines each category with more granularity, distinguishing, for example, between tumors invading the lung versus those invading the aorta or windpipe.
Diagnosis: Biopsy or Straight to Surgery
If a CT scan reveals a well-contained mass in the anterior mediastinum that looks like a thymoma, surgeons often proceed directly to removal without a preliminary biopsy. Taking a piece of tissue first carries its own risks, including potentially seeding tumor cells along the needle track, and if the tumor is clearly resectable, surgery accomplishes both diagnosis and treatment in one step.
When imaging suggests the tumor is invading surrounding structures, the approach changes. These cases typically need chemotherapy or a combination of chemotherapy and radiation before surgery to shrink the tumor and make complete removal possible. In that scenario, a needle biopsy or small surgical biopsy is performed first to confirm the diagnosis before starting treatment.
Surgical Treatment
Surgery is the cornerstone of thymoma treatment and the only approach that offers a chance of cure. The traditional method is an open operation through the breastbone (median sternotomy), which gives the surgeon the widest view and access. For more complex cases involving invasion of nearby organs, larger incisions may be needed.
Minimally invasive options have become well established. Video-assisted thoracoscopic surgery and robotic-assisted approaches offer equivalent or even better outcomes for appropriately selected tumors, with fewer perioperative complications and faster recovery. These can be performed through the chest from the right or left side, from both sides, through a small incision below the tip of the breastbone, or through the neck, depending on the tumor’s position and the surgeon’s expertise.
The goal is always to remove the entire tumor with no cancer cells at the cut edges. A complete resection is the single strongest predictor of long-term survival.
Chemotherapy and Radiation
For tumors that cannot be fully removed surgically, or that have already spread, chemotherapy becomes important. The most commonly used regimens are built around cisplatin, a platinum-based drug, combined with other agents. Common combinations include cisplatin with doxorubicin and cyclophosphamide, or cisplatin with etoposide and ifosfamide. Carboplatin paired with paclitaxel is another first-line option.
Chemotherapy may be given before surgery to shrink a tumor that initially appears too large or too invasive for a clean removal. It can also be given after surgery if the tumor was not completely resected or if the pathology shows an aggressive subtype. For people whose disease progresses after initial chemotherapy, several single-agent options exist, including pemetrexed, gemcitabine, and paclitaxel.
Radiation therapy is commonly used after surgery when the tumor was invasive or when margins were close. It can also be part of the upfront treatment plan alongside chemotherapy for locally advanced disease. Because the thymus sits near the heart and lungs, modern radiation techniques focus the beam tightly on the target to limit damage to surrounding tissue.
Prognosis and What to Expect Long Term
Thymoma generally carries a better prognosis than most solid tumors. Stage I disease, with a completely encapsulated tumor, has excellent long-term survival rates after surgery alone. Even stage II and III tumors often do well with complete resection and appropriate follow-up treatment. The WHO subtype matters here: types A, AB, and B1 tend to have more favorable outcomes, while B2, B3, and thymic carcinoma carry progressively higher risks of recurrence.
One distinctive feature of thymoma is that recurrences can appear many years, sometimes over a decade, after initial treatment. This makes long-term follow-up with periodic imaging essential, even when the original surgery went well. Recurrences in the chest lining can sometimes be surgically removed again, and even patients with recurrent disease often live for many years with appropriate management.